Notice of Results and Investor Presentation

Celadon Pharmaceuticals PLC

18 September 2023

 

Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

Notice of Results and Investor Presentation

LONDON, 18 September 2023: Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, will announce its results for the six months ended 30 June 2023 on Thursday 28 September 2023.

Analyst Briefing: 10.00am BST, Thursday 28 September 2023

Management will host a virtual analyst presentation followed by a Q&A session at 10.00am BST on Thursday 28 September 2023. Analysts wishing to join should register their interest by contacting [e-mail].

Investor Presentation: 3.30pm BST, Thursday 28 September 2023

Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 3.30pm BST on Thursday 28 September 2023.

The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor

Investors who already follow Celadon on the Investor Meet Company platform will automatically receive an invitation to the event.

Enquiries:

Celadon Pharmaceuticals Plc
James Short, CEO Arthur Wakeley, MD Jonathan Turner, CFO	Via Powerscourt
Canaccord Genuity Limited (Nominated Adviser and Broker)
Bobbie Hilliam / Max Hartley	[phone]
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums	[phone] [e-mail]

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its GMP pharmaceutical cannabis product. The Group owns an approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.co.uk

 

END